Because atrial fibrillation increases the risk for stroke, especially among those with other underlying conditions, what anticoagulation therapies should be considered for these patients? Dr. Stuart Connolly, professor of medicine and director of the division of cardiology and the Salim Yusuf Chair in Cardiology at McMaster University in Ontario, Canada, weighs the benefits and risks of different anticoagulation therapies, in the context of the recent Randomized Evaluation of Long-Term Anticoagulation Therapy (or, RE-LY) trial. In addition to the standard warfarin and aspirin anticoagulants, there are now two promising new classes of anticoagulation therapy. How effective is dabigatran, compared to warfarin? What questions do we still need answered about anticoatulantion therapies that will be addressed in the years to come? Hosted by Dr. Janet Wright.
Produced in Cooperation with
